|Bid||72.00 x 800|
|Ask||71.68 x 800|
|Day's Range||83.65 - 87.81|
|52 Week Range||39.11 - 93.58|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||1,086.38|
|Earnings Date||Jul 30, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.50|
GAITHERSBURG, Md., June 05, 2020 -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl).
The contract development and manufacturing organization will support a number of SARS-CoV-2 vaccine candidates.
As drugmakers race to develop vaccines, tests and therapies for the disease, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development. "Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted," Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement. The HHS task order with Emergent falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds disease-fighting technology.
The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine. As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development. "Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted," Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement.
Emergent BioSolutions Inc. (EBS) today announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines. “Emergent is proud of this expanded BARDA partnership that symbolizes confidence in our development and manufacturing capabilities that have served the U.S. government’s needs for more than two decades,” said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent Biosolutions Inc. has been strong and could climb still further in the months ahead. In the daily bar chart of EBS, below, we can see that the stock made a seven-month consolidation pattern around $55 before its upside breakout. The On-Balance-Volume (OBV) line is in an uptrend from August and its rise tells us that buyers of EBS have been more aggressive for several months now.
The Emergent BioSolutions (NYSE:EBS) share price has done well in the last month, posting a gain of 32%. Zooming out...
At its worst on March 23rd, Dow Jones and the S&P declined by around 37% and 34%. At the time, those kinds of numbers represented a loss of a 3-year gain since Trump’s election in November of 2016. Measured by VIX, market volatility spiked by 43% in March, reaching levels that are comparable to the […]
The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19. And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs.
The stock of Emergent BioSolutions (NYSE: EBS) has been on fire of late. The company has been involved in the race to develop a vaccine for COVID-19. Specifically, Emergent signed several contract development and manufacturing agreements with other companies that are currently developing vaccines for the coronavirus.
GAITHERSBURG, Md., May 12, 2020 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the.
It's great to see Emergent BioSolutions (NYSE:EBS) shareholders have their patience rewarded with a 34% share price...
Emergent BioSolutions Inc. (EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 21, 2020 at 9:00 AM EDT. The Company, which disclosed the move to virtual-only format in all proxy materials related to the 2020 Annual Meeting of Stockholders, has taken this step to support the health and well-being of meeting participants in light of the COVID-19 pandemic. As described in the proxy materials, stockholders of record as of the record date of March 26, 2020 are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2020 and entering their 16-digit Control Number provided on the proxy card, voting instruction form or notice received from the Company to log into this website.
On Mad Money Monday night, Jim Cramer spoke with Robert Kramer, CEO of Emergent BioSolutions Inc. , one of many vaccine makers in the race to stop Covid-19. Kramer said that Emergent has a long history of focusing on public health threats. In the daily bar chart of EBS, below, we can see that prices began a strong upside move in late August long before the words "coronavirus" and "pandemic" entered our vocabulary.
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Emergent BioSolutions Earnings Conference Call. My name is Bob Burrows. As is customary, today's call is open to all participants, and in addition, the call is being recorded and is copyrighted by Emergent BioSolutions.
Reaffirms full year 2020 financial forecastExecutes multi-faceted response to COVID-19 drawing upon longstanding investments in capabilities to address public health threats, as.
The company recently ended up grabbing quite a bit of investor attention thanks to a recently announced partnership with Johnson & Johnson (NYSE: JNJ) to help manufacture the latter's COVID-19 vaccine. Over the past month, the company has signed agreements with a number of other COVID-19 vaccine makers as well. Does all this make Emergent BioSolutions the next hot coronavirus stock, one you should keep on your watch list?
Johnson & Johnson tapped Emergent Biosolutions to help manufacture 1 billion doses of its experimental coronavirus vaccine — sending Emergent Biosolutions stock flying on Friday.
Emergent BioSolutions and Johnson & Johnson signed a $135 million accord to produce J&J;'s lead candidate for a vaccine against coronavirus.
D.C. Mayor Muriel Bowser said Thursday the District would hire hundreds of contact tracers to help with the city’s efforts to track the spread of the coronavirus, one of several efforts in Greater Washington geared toward the reopening of the local economy. Maryland Gov. Larry Hogan rolled out a larger contact tracing initiative earlier this week that he said will be able to track up to 1,000 cases a day. Virginia Gov. Ralph Northam on Thursday extended a statewide ban on elective surgeries by one week, to May 1.
Shares of Johnson & Johnson were up 0.4% in premarket trading on Friday after the company announced a manufacturing deal with Emergent BioSolutions Inc. for its COVID-19 vaccine candidate. Emergent's stock gained 7.4% before the market opened. J&J has said it plans to launch Phase 1 clinical studies of its vaccine in September, and this deal is part of efforts to ramp up manufacturing capacity. J&J will pay Emergent $135 million, per the agreement, according to Emergent. "We believe that J&J has selected Emergent to be its U.S. based manufacturer of the vaccine," Chardon analysts wrote in a note on Friday. Year-to-date, J&J's stock has gained 6.6%, shares of Emergent are up 23.4%, and the S&P 500 is down 13.4%.